Open Access

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

  • Jashodeep Datta1,
  • Erik Berk1,
  • Shuwen Xu1,
  • Elizabeth Fitzpatrick1,
  • Cinthia Rosemblit1,
  • Lea Lowenfeld1,
  • Noah Goodman2,
  • David A Lewis2,
  • Paul J Zhang4,
  • Carla Fisher1,
  • Robert E Roses1,
  • Angela DeMichele2, 3 and
  • Brian J Czerniecki1, 5Email author
Breast Cancer Research201517:71

https://doi.org/10.1186/s13058-015-0584-1

Received: 23 March 2015

Accepted: 13 May 2015

Published: 23 May 2015

Abstract

Introduction

A progressive loss of circulating anti-human epidermal growth factor receptor-2/neu (HER2) CD4+ T-helper type 1 (Th1) immune responses is observed in HER2pos-invasive breast cancer (IBC) patients relative to healthy controls. Pathologic complete response (pCR) following neoadjuvant trastuzumab and chemotherapy (T + C) is associated with decreased recurrence and improved prognosis. We examined differences in anti-HER2 Th1 responses between pCR and non-pCR patients to identify modifiable immune correlates to pathologic response following neoadjuvant T + C.

Methods

Anti-HER2 Th1 responses in 87 HER2pos-IBC patients were examined using peripheral blood mononuclear cells pulsed with 6 HER2-derived class II peptides via IFN-γ ELISPOT. Th1 response metrics were anti-HER2 responsivity, repertoire (number of reactive peptides), and cumulative response across 6 peptides (spot-forming cells [SFC]/106 cells). Anti-HER2 Th1 responses of non-pCR patients (n = 4) receiving adjuvant HER2-pulsed type 1-polarized dendritic cell (DC1) vaccination were analyzed pre- and post-immunization.

Results

Depressed anti-HER2 Th1 responses observed in treatment-naïve HER2pos-IBC patients (n = 22) did not improve globally in T + C-treated HER2pos-IBC patients (n = 65). Compared with adjuvant T + C receipt, neoadjuvant T + C — utilized in 61.5 % — was associated with higher anti-HER2 Th1 repertoire (p = 0.048). While pCR (n = 16) and non-pCR (n = 24) patients did not differ substantially in demographic/clinical characteristics, pCR patients demonstrated dramatically higher anti-HER2 Th1 responsivity (94 % vs. 33 %, p = 0.0002), repertoire (3.3 vs. 0.3 peptides, p < 0.0001), and cumulative response (148.2 vs. 22.4 SFC/106, p < 0.0001) versus non-pCR patients. After controlling for potential confounders, anti-HER2 Th1 responsivity remained independently associated with pathologic response (odds ratio 8.82, p = 0.016). This IFN-γ+ immune disparity was mediated by anti-HER2 CD4+T-bet+IFN-γ+ (i.e., Th1) — not CD4+GATA-3+IFN-γ+ (i.e., Th2) — phenotypes, and not attributable to non-pCR patients’ immune incompetence, host-level T-cell anergy, or increased immunosuppressive populations. In recruited non-pCR patients, anti-HER2 Th1 repertoire (3.7 vs. 0.5, p = 0.014) and cumulative response (192.3 vs. 33.9 SFC/106, p = 0.014) improved significantly following HER2-pulsed DC1 vaccination.

Conclusions

Anti-HER2 CD4+ Th1 response is a novel immune correlate to pathologic response following neoadjuvant T + C. In non-pCR patients, depressed Th1 responses are not immunologically “fixed” and can be restored with HER2-directed Th1 immune interventions. In such high-risk patients, combining HER2-targeted therapies with strategies to boost anti-HER2 Th1 immunity may improve outcomes and mitigate recurrence.

Introduction

Human epidermal growth factor receptor-2 (HER2)/neu overexpression, a molecular oncodriver in 20–25 % of breast cancers (BC) [1], is associated with an aggressive clinical course and poor overall prognosis [2]. The availability of HER2-targeted therapies (e.g., trastuzumab, lapatinib, etc.) has dramatically improved outcomes in patients with HER2-positive (HER2pos) BC [3, 4]. In contemporary practice, patients with larger resectable tumors often benefit from neoadjuvant administration of trastuzumab and chemotherapy (T + C), with nearly 40–60 % achieving pathologic complete response (pCR) [57]; compared with incomplete response (non-pCR), pCR is associated with decreased recurrence and improved long-term survival [7, 8]. While absent estrogen/progesterone receptor (ER/PR) expression appears to reproducibly correlate with pCR [8, 9], there are a paucity of modifiable immune signatures that are associated with response and/or resistance to neoadjuvant T + C.

Utilizing a prospective cohort, we have recently demonstrated a progressive loss in anti-HER2 CD4+ T-helper type-1 (Th1) immunity across a tumorigenesis continuum in HER2pos BC [10]. Interestingly, HER2-specific Th1 responses are preserved in healthy volunteers and patients harboring HER2neg (0–1+) invasive breast cancer (IBC). In patients with HER2pos IBC, this anti-HER2 Th1 deficit is not impacted by standard therapies (i.e., surgical resection, radiation, or T + C treatment), but can be restored following HER2-pulsed type-1-polarized dendritic cell (DC1) vaccinations. Moreover, depressed anti-HER2 Th1 responses predict an increased risk of subsequent recurrence in patients treated with adjuvant T + C [10]. These observations prompted us to investigate whether similar depressed anti-HER2 Th1 responses are observed in another known harbinger of recurrence, non-pCR status following neoadjuvant T + C [8]; conversely, we hypothesized that preservation/restoration of anti-HER2 Th1 responses may be associated with pCR.

In this study, we identified elevated anti-HER2 CD4+ Th1 response as a novel systemic immune correlate to pCR following neoadjuvant T + C in patients with HER2pos IBC. Relatively depressed anti-HER2 Th1 responses in patients with non-pCR are not attributable to host-level T cell anergy, loss of immunocompetence, or increase in circulating immunosuppressive phenotypes. Importantly, this anti-HER2 Th1 deficit in patients with non-pCR is not fixed, and can be corrected with CD4+ Th1-directed immune manipulations via HER2-targeted DC1 vaccinations. To the best of our knowledge, these observations represent the first demonstration of a modifiable host-level oncodriver (HER2/neu)-specific immune disparity that is associated with pathologic response to neoadjuvant T + C. These findings may have important implications for immune monitoring and/or design of adjunctive immune therapies to improve outcomes in trastuzumab-treated HER2pos BC patients.

Methods

Study design

After approval by the Institutional Review Board of the University of Pennsylvania, 87 patients with HER2pos IBC were enrolled in a non-biased fashion (Table 1). Eligible patients had histologically confirmed IBC, HER2/neu overexpression (i.e., immunochemistry (IHC) 3+ or 2+/fluorescence in situ hybridization (FISH)-positive) confirmed at our institution, no evidence of distant metastasis, and were not receiving immunosuppressive medications. Informed consent was obtained from all participants. Anti-HER2 CD4+ Th1 responses of recruited subjects were analyzed prospectively. Anti-HER2 Th1 responses in treatment-naïve (i.e., not receiving definitive therapy at enrollment) stage I–III HER2pos IBC patients (n = 22) were established as an immunologic "baseline", and were compared with Th1 responses in stage I–III HER2pos IBC patients who had completed T + C treatment (n = 65; i.e., either neoadjuvant or adjuvant T + C plus definitive surgery). In patients treated with T + C, analyses were stratified by sequence of chemotherapy (i.e., neoadjuvant versus adjuvant), and further sub-stratified by pCR and non-pCR status within the neoadjuvant cohort (Fig. 1). pCR was defined as absence of residual invasive cancer on pathologic examination of resected breast specimen(s) and sampled lymph nodes (i.e., ypT0/Tis ypN0).
Table 1

Demographic and tumor-related characteristics of the study population: age, race, AJCC pathologic stage, hormone receptor status, and time from completion of trastuzumab (when applicable)

Characteristic

Treatment-naïve HER2pos IBC (n = 22)

HER2pos IBC treated with T + C (n = 65)

  

Neoadjuvant (n = 40)

Adjuvant (n = 25)

Age, years, mean ± standard error

56.8 ± 3.1

45.9 ± 2.1

57.2 ± 2.6

Age, years, range

36–88

24–81

28–85

Race/ethnicity, number (%)

   

 Caucasian

17 (77.3)

35 (87.5)

19 (76.0)

 African-American

2 (9.1)

3 (7.5)

4 (16.0)

 Asian

2 (9.1)

1 (2.5)

0 (0)

 Hispanic

1 (4.5)

1 (2.5)

2 (8.0)

AJCC stage at diagnosisa, number (%)

   

 Stage 1

14 (63.6)

0 (0)

6 (24.0)

 Stage 2

6 (27.3)

21 (52.5)

15 (60.0)

 Stage 3

2 (9.1)

19 (47.5)

4 (16.0)

Hormone receptor status, number (%)

   

 ER/PRpos

12 (54.5)

18 (45.0)

11 (44.0)

 ER/PRneg

10 (45.5)

22 (55.0)

14 (56.0)

Time from completion of trastuzumab to study enrollment, number (%)

   

 <6 months

 

18 (45.0)

10 (40.0)

 ≥6 months

 

22 (55.0)

15 (60.0)

aFor neoadjuvant cohort, AJCC clinical stage is shown. HER2 pos Human epidermal growth factor receptor overexpressing, IBC invasive breast cancer, T + C trastuzumab and chemotherapy, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor

Fig. 1

Consolidated Standards of Reporting Trials (CONSORT) diagram of the study population. In this study, 87 patients with human epidermal growth factor receptor 2-positive (HER2 pos ) breast cancer were enrolled; all tumors were histologically confirmed as invasive breast cancer (IBC) with HER2 overexpression (3+ or 2+/fluorescence in situ hybridization (FISH)-positive). Cohorts are labeled (ag) for ease of comparison (of immune responses), and are referred to in Results. Time points at which blood was drawn are indicated (red callout boxes). Median follow up in the cohort treated with trastuzumab and chemotherapy (T + C) was 26 (IQR 16.5–31.0) months. pCR pathologic complete response, DCI type 1-polarized dendritic cell, Adj adjuvant, mo months

Four patients with non-pCR were recruited to our adjuvant HER2-pulsed DC1 vaccination trial (NCT02061423); anti-HER2 Th1 responses in these patients were compared pre-immunization and post-immunization.

Immune response detection

Circulating anti-HER2 CD4+ Th1 responses were examined in unexpanded peripheral blood mononuclear cells (PBMC) pulsed ex vivo with six HER2-derived class II peptides (42–56, 98–114, 328–345, 776–790, 927–941, 1166–1180 [11]), by measuring IFN-γ production via enzyme-linked immunosorbent spot (ELISPOT) assays. ELISPOT was performed as previously described [10, 12]. Briefly, polyvinylidene fluoride (PVDF) membrane plates (Mabtech Inc., Cincinnati, OH, USA) were coated with anti-IFN-γ capture antibody. After plates were blocked, cryopreserved PBMCs, isolated using density gradient centrifugation, were plated in triplicate (2 × 105 cells/well) and incubated at 37 °C for 24–36 h with either HER2 peptides (4 μg; Genscript, Piscataway, NJ, USA); media alone (unstimulated control); or positive control (anti-human CD3/CD28 antibodies (0.5 μg/mL; BD Pharmingen, San Jose, CA, USA)). After washing, biotinylated detection antibody (100 μg/mL) and 1:1000-diluted streptavidin-horseradish peroxidase (HRP) in PBS + 0.5 % FCS were added serially, and addition of 3,3′-5,5′ tetramethylbenzidin (TMB) substrate solution revealed spot formation. Spot-forming cells (SFC) were counted using an automated reader (ImmunoSpot CTL, Shaker Heights, OH, USA).

PBMC from HLA-A2.1pos donors were stimulated with two HER2-derived class I peptides (369–377, 689–697) [11]; phorbol-12-myristate 13-acetate (PMA, 50ng/mL) and ionomycin (1μg/mL; Sigma-Aldrich, St. Louis, MO, USA) served as positive control. HLA-A2.1 typing (LABType® SSO) was performed in the Clinical Immunology laboratory at the Hospital of the University of Pennsylvania. In addition, HER2-specific IL-4 and IL-10 production (surrogates for T-helper type-2 (Th2) and regulatory T-cell (Treg) cell function, respectively) were measured by ELISPOT [13]. Recall Th1 responses were examined by stimulating PBMC with 1:100-diluted recall stimuli Candida albicans (Allermed Laboratories, San Diego, CA, USA) and tetanus toxoid (Santa Cruz Biotechnology, Dallas, TX, USA).

An empiric method of determining anti-HER2 Th1 response specificity was employed [10]. A positive response to an individual HER2 peptide was defined as: (a) threshold minimum of 20 SFC/2 × 105 cells in experimental wells after subtracting unstimulated background; and (b) ≥2-fold increase in antigen-specific SFCs over background. Three metrics of anti-HER2 Th1 response were defined for each cohort: (a) responsivity (proportion of patients responding to ≥1 peptide), (b) repertoire (mean number of reactive peptides), and (c) cumulative response across 6 peptides (SFC/106 cells). A sample calculation is illustrated in Additional file 1: Figure S1. Inter-assay precision of ELISPOT assays was validated as described previously [14].

Flow cytometry

PBMC suspensions were prepared in FACS buffer (PBS + 1 % FCS + 0.01 % azide) and anti-human CD3, CD4, CD8, CD83, HLA-DR, CD11b, CD33, CD19, CD16 (BD Bioscience, San Jose, CA, USA), CD4, and CD25 (Biolegend, San Diego, CA, USA) were used to determine the relative PBMC immunophenotype. After washing, cells were incubated for 30 minutes at room temperature (RT) with antibody mixtures. Following incubation, cells were washed/fixed with 2 % paraformaldehyde. Intracellular staining with anti-FoxP3 (eBioscience, San Diego, CA, USA) using the FoxP3 fixation/permeabilization kit (Biolegend) was performed according to manufacturer’s instructions. Analysis was performed using the BD LSR-II cytometer, and datasets were analyzed using CellQuest Pro software.

Th1 vs Th2 contributions to anti-HER2 IFN-γ+ T cells

PBMC were resuspended at 1.2 × 106 cells/mL in DMEM + 5 % human serum in 24-well plates, and pulsed with HER2-class II peptide mix (24 μg/mL). Unstimulated and anti-CD3/CD28 antibody-pulsed PBMCs from each donor served as negative and positive controls, respectively. Following incubation for 6 h at 37 °C, protein transport inhibitor Brefeldin-A (Sigma Aldrich; 10 μg/mL) was added to each sample, and incubated overnight. Following washing, cells were stained with anti-CD4 for 30 minutes at RT. Cells were washed twice, fixed and permeabilized as described above, and stained with anti-T-bet, anti-GATA-3 and anti-IFN-γ (Biolegend) for 30 minutes. After incubation, cells were washed and analyzed using the BD LSR-II cytometer.

Vaccination procedure and trial design

We have initiated a phase I adjuvant HER2-pulsed DC1 vaccination trial for patients with HER2pos IBC with residual disease following neoadjuvant T + C (NCT02061423). Eligible patients are 18 years or older, have Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, and have biopsy-proven stage I–III HER2pos IBC. The primary endpoint of this trial is safety/feasibility; however, we report an interim analysis of anti-HER2 immune responses following vaccination (a secondary endpoint) in recruited patients (n = 4) as proof of principle of its immunogenicity in this heavily pre-treated population.

Monocytic dendritic cell precursors (CD14pos peripheral blood monocytes) were obtained from subjects via tandem leukapheresis/countercurrent centrifugal elutriation. Dendritic cells (DCs) were cultured overnight in macrophage serum-free medium (Cellgro, Manassas, VA, USA) with granulocyte monocyte colony stimulating factor (GM-CSF, 250 IU/mL; Berlex, San Pablo, CA, USA) and IL-4 (1000 u/mL; R&D Systems, Minneapolis, MN, USA) - these are considered immature DCs (iDCs). The following day, iDCs were pulsed with the aforementioned six HER2 major histocompatability class (MHC)-II promiscuous-binding peptides (42–56, 98–114, 328–345, 776–790, 927–941, 1166–1180). After 8–12 h incubation, IFN-γ (1000 U/mL) was added; the following day, National Institutes of Health (NIH) reference standard lipopolysaccharide (LPS) was added (10 ng/mL) to achieve full DC activation to a DC1 phenotype 6 h before harvest. For HLA-A2.1pos patients, DC1 were pulsed with two MHC class I binding peptides (369–377, 689–697). Harvested cells were washed and lot release criteria of >70 % viability, negative Gram stain, and endotoxin <5 EU/kg confirmed.

Immunizations were administered in the NIH-designated General Clinical Research Center at the Hospital of the University of Pennsylvania. Injections comprised 10–20 × 106 HER2-pulsed DC1s suspended in 1 mL sterile saline, and administered by ultrasound guidance into groin lymph nodes [12, 15]. Immunizations were administered once weekly for 6 weeks, followed by three booster doses spaced 3 months apart.

Statistical analysis

Descriptive statistics summarized distributions of patient characteristics and immune response variables. Data transformation of the cumulative response variable (natural log or square root) was applied to meet the assumptions of parametric testing, where applicable. The unpaired or paired Student’s t test (parametric continuous data), Mann–Whitney (non-parametric continuous data), and chi square (χ 2) tests (categorical data) were used for two-group and univariate comparisons between pCR and non-pCR cohorts. To determine independent correlates of pCR, variables with a trend toward significance on univariate testing (p <0.20) were entered into a forward, stepwise multivariable logistic regression model (p <0.05 for entry, p <0.10 for exit). A p value <0.05 was considered statistically significant. All tests were two-sided. Analyses were performed using Prism 5.0 (GraphPad Inc., La Jolla, CA, USA) and SPSS version 22 (IBM Corp, Chicago, IL, USA).

Results

Patient characteristics

In the overall cohort (n = 87), mean age was 51.4 ± 1.5 (range 24–88) years and a majority (81.6 %) were white. Demographic and tumor-related characteristics of participants are detailed in Table 1. Of the cohort treated with T + C (n = 65), neoadjuvant T + C was administered in 40 patients (61.5 %); 16 patients (40.0 %) achieved pCR whereas 24 (60.0 %) had residual disease at surgery (non-pCR). Median follow up in patients treated with T + C was 26 (IQR 16.5–31) months (Fig. 1).

In patients treated with neoadjuvant T + C, mean age and body mass index (BMI) were 45.9 ± 2.1 years and 32.3 ± 2.1 kg/m2, and a majority were white (87.5 %) or premenopausal (57.5 %). More than half of patients had ER/PRneg tumors (55.0 %) or clinical stage II disease at diagnosis (52.5 %). Among pathologic features, lymphovascular invasion (LVI) and nuclear grade 3 were observed in 7 (17.5 %) and 26 (65.0 %) tumors, respectively. The most commonly utilized treatment regimen and operative approach was Adriamycin/Cyclophosphamide/Taxol/Herceptin (AC/TH; 82.5 %) and mastectomy (67.5 %), respectively.

Depressed anti-HER2 CD4+ responses in treatment-naïve HER2pos IBC patients are not globally restored following T + C

Using PBMCs, we compared IFN-γ+ anti-HER2 CD4+ T-cell responses between HER2pos IBC cohorts via HER2-stimulated IFN-γ ELISPOT. We have previously demonstrated a striking loss of anti-HER2 Th1 responses in treatment-naïve HER2pos IBC patients relative to healthy donors [10]. In the current study, depressed anti-HER2 Th1 responses in treatment-naïve HER2pos IBC patients (cohort A; Fig. 1) – assessed by responsivity, repertoire, or cumulative response – did not improve globally in HER2pos IBC patients treated with T + C (cohort B; Fig. 2a). Among T + C – treated patients, neoadjuvant T + C receipt (cohort D) was associated with higher anti-HER2 Th1 repertoire (1.5 ± 0.3 vs. 0.8 ± 0.4; p = 0.048), but not responsivity or cumulative response, compared with adjuvant T + C treatment (cohort C; Fig. 2b).
Fig. 2

Interferon (IFN)-γ+ anti-human epidermal growth factor receptor 2 (HER2) CD4+ T cell response variations in HER2pos patients with invasive breast cancer (IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed peripheral blood mononuclear cells examined anti-HER2 CD4+ T cell responses in patients with HER2pos IBC, stratified by anti-HER2 responsivity, response repertoire (mean # of reactive peptides), and cumulative response (mean total SFC/10 6 cells). Differences between (a) Treatment-naïve patients with HER2pos IBC (n = 22) and those treated with trastuzumab and chemotherapy (T + C) (n = 65); and (b) patients treated with Neoadjuvant T + C (n = 40) and those treated with Adjuvant T + C (n = 25). SFC spot-forming cells

Anti-HER2 T cell immune responses correlate strongly with pCR

In the cohort receiving neoadjuvant T + C, patients achieving pCR (cohort E; Fig. 1) demonstrated dramatically higher IFN-γ+ anti-HER2 Th1 responsivity (93.8 % vs 33.3 %, p = 0.0002), repertoire (3.3 ± 0.3 vs 0.3 ± 0.1, p <0.0001), and cumulative response (148.2 ± 24.6 vs 22.4 ± 3.0, p <0.0001) compared with non-pCR patients (cohort F; Fig. 3a). Of note, median duration from initiation of neoadjuvant T + C to study enrollment did not differ between pCR and non-pCR cohorts (23.5 vs 26.5 months, p = 0.44).
Fig. 3

Significant disparity in anti-human epidermal growth factor receptor 2 (anti-HER2) interferon (IFN)-γ+ T cell immune responses between patients with pathologic complete response (pCR) and patients with non-pCR. a Significantly elevated anti-HER2 CD4+ T cell responses by IFN-γ enzyme-linked immunosorbent spot analysis (ELISPOT) are observed in patients with HER2pos invasive breast cancer achieving pCR (n = 16) following neoadjuvant trastuzumab and chemotherapy (T + C), compared with patients with non-pCR (n = 24). Peripheral blood mononuclear cells (PBMC) from patients with pCR and non-pCR were stimulated ex vivo with six HER2-derived class II peptides and IFN-γ production via ELISPOT was compared. Responses are stratified by anti-HER2 responsivity, repertoire, and cumulative response. b Evaluable HLA-A2.1pos PBMC from patients with pCR (n = 6; black bars) and non-pCR (n = 4; white bars) were stimulated ex vivo with two HER2-derived class I peptides, HER2 369377 and HER2 689–697, and IFN-γ production via ELISPOT was compared. Phorbol-12-myristate 13-acetate (PMA) and ionomycin served as positive control. Results are expressed as mean spot-forming cells (SFC)/2 × 105 cells ± standard error of the mean

Evaluable PBMC from HLA-A2.1pos pCR and non-pCR patients were stimulated ex vivo with two HER2-derived class I peptides. Compared with non-pCR patients, IFN-γ+ CD8+ T cell responses were significantly higher in pCR patients upon stimulation with the immunodominant HER2369–377 (72.1 ± 10.2 vs 12.1 ± 2.4 SFC/2 × 105, p = 0.002) epitope, but not the subdominant HER2689–697 (21.5 ± 3.7 vs 17.3 ± 4.0 SFC/2 × 105, p = 0.47) epitope (Fig. 3b).

Anti-HER2 Th1 responsivity is independently associated with pCR following multivariable analysis

The independent association between IFN-γ+ anti-HER2 Th1 responses and pCR was evaluated by controlling for confounding from relevant demographic and clinicopathologic characteristics. Upon univariate testing, pCR and non-pCR cohorts did not differ significantly by age, menopausal status, race, BMI, comorbidity, presence of LVI, nuclear grade, or utilized T + C regimens. However, pCR patients were more likely to have ER/PRneg tumors compared with patients with non-pCR (68.8 % vs 29.2 %, p = 0.02). Although pCR patients demonstrated a trend toward presentation at lower (i.e., stage II) clinical stage (68.8 % vs 41.7 %, p = 0.12) and less frequent need for mastectomy (50.0 % vs 79.2 %, p = 0.09), these comparisons did not reach statistical significance (Table 2).
Table 2

Univariate comparison of demographic and tumor-related characteristics between pCR and non-pCR patients

Characteristic

Patients with pCR, number (%) or median (IQR)

Patients with non-pCR, number (%) or median (IQR)

P value

Overall population

16 (40)

24 (60)

--

Age (years), median

45.5 (35.5–51.5)

49.5 (34.3–53.0)

0.97

BMI (kg/m2), median

25.7 (23.3–29.6)

27.3 (24.2–31.0)

0.49

Race

  

0.63

 White

15 (93.8)

20 (83.3)

 Black/Asian/Hispanic

1 (6.2)

4 (16.7)

Charlson comorbidity index

  

0.75

 <2 (mild)

7 (43.8)

9 (37.5)

 ≥2 (moderate–high)

9 (56.2)

15 (62.5)

Menopausal status

  

1.00

 Premenopausal

9 (56.2)

14 (58.3)

 Postmenopausal

7 (43.8)

10 (41.7)

AJCC clinical stageb

  

0.12

 II

11 (68.8)

10 (41.7)

 III

5 (31.2)

14 (58.3)

ER/PR statusb

  

0.02

 Positive

5 (31.2)

17 (70.8)

 Negative

11 (68.8)

7 (29.2)

Lymphovascular invasion

  

0.21

 Absent

15 (93.8)

18 (75.0)

 Present

1 (6.2)

6 (25.0)

Nuclear grade

  

0.33

 Grade 1/2

4 (25.0)

10 (41.7)

 Grade 3

12 (75.0)

14 (58.3)

Neoadjuvant regimen

  

1.00

 AC/TH

13 (81.3)

20 (83.3)

 Othera

3 (18.7)

4 (16.7)

Operative approachb

  

0.09

 BCS + XRT

8 (50.0)

5 (20.8)

 Mastectomy ± XRT

8 (50.0)

19 (79.2)

aOther included carboplatin/taxotere/trastuzumab and taxotere/cyclophosphamide/trastuzumab. bIncluded in multivariable logistic regression analysis to determine independent correlates to pCR. pCR pathologic complete response, BMI body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, XRT radiotherapy

Relevant clinicopathologic variables on univariate testing (i.e., ER/PR status, clinical stage, operative approach) and anti-HER2 responsivity (Th1 repertoire and cumulative response were highly co-linear) were entered into a multivariable logistic regression analysis. Anti-HER2 Th1 responsivity (odds ratio (OR) 8.82, 95 % CI 1.50, 51.83, p = 0.016) and ER/PR status (OR 4.71, 95 % CI 1.03, 21.58, p = 0.046) remained independently associated with pCR status.

Due to persistence of the association between ER/PR status and pCR on multivariable analysis, anti-HER2 Th1 responses were stratified by hormone receptor status. No significant differences in anti-HER2 Th1 responsivity (72.2 % vs 50.0 %, p = 0.23), repertoire (1.9 ± 0.4 vs 1.1 ± 0.4, p = 0.12), or cumulative response (80.6 ± 18.7 vs 64.8 ± 20.3, p = 0.57) were observed between ER/PRneg (n = 22) and ER/PRpos (n = 18) patients, respectively.

Th1 is the predominant phenotype contributing to anti-HER2 IFN-γ+ CD4+ T cell deficit

In order to ascertain the CD4+ T cell phenotype most contributory to the anti-HER2 IFN-γ+ immune deficit, HER2-stimulated PBMC were assessed for co-expression of T-bet (Th1 transcription factor [16]) or GATA-3 (Th2 transcription factor [17]), and intracellular IFN-γ by flow cytometry. Patients with pCR demonstrated a significantly greater proportion of HER2-specific CD4+T-bet+IFN-γ+ (0.25 ± 0.1 % vs 0.02 ± 0.01 %, p = 0.039), but not CD4+GATA-3+IFN-γ+ (0.02 ± 0.01 % vs 0.03 ± 0.01 %, p = 0.49) or CD4+GATA-3+IFN-γ (0.24 ± 0.03 % vs 0.27 ± 0.03 %, p = 0.52) PBMC, compared with patients with non-pCR (Fig. 4a).
Fig. 4

Anti-human epidermal growth factor receptor 2 (anti-HER2) CD4+ T-helper type-1 (Th1) is the dominant phenotype contributing to interferon-γ+ (IFN-γ + ) CD4 + T cell deficit in patients without pathologic complete response (non-pCR). a Relative contributions of Th1 (T-bet + IFN-γ + ) versus Th2 (GATA-3 + IFN-γ + ) phenotypes to HER2 peptide-specific IFN-γ+ cells in peripheral blood mononuclear cells (PBMC) from pCR and non-pCR patients. Representative stains within groups are shown after gating on CD4+ cells; results in adjoining histograms are expressed as mean proportions (%) ± standard error of the mean (SEM) as indicated. b Circulating HER2-specific IL-4 production does not vary between pCR and non-pCR patients, when assessed by responsivity, repertoire, and cumulative response. Results expressed as proportion or mean ± SEM (top panel). Donor-matched cumulative IFN-γ and IL-4 production (spot-forming cells (SFC)/106 cells) across six HER2 class II peptides compared in pCR and non-pCR patients. Relative HER2-specific IFN-γ:IL-4 proportions (% depicted in graph) was significantly higher in pCR (IFN-γ/(IFN-γ + IL-4) = 73.9 %:IL-4/(IFN-γ + IL-4) = 26.1 %) compared with non-pCR patients (34.6 %:65.4 %). Absolute IFN-γ:IL-4 production ratio changed from 2.8:1 (pCR) to 0.5:1 (non-pCR) (bottom left panel). No relative shifts in IFN-γ:IL-4 production were observed to positive controls (anti-CD3/CD28 or anti-CD3, respectively) (bottom right panel). c HER2-specific IL-10 production is similar between pCR and non-pCR patients across all Th1 metrics. Results are expressed as proportion or mean ± SEM (top panel). Relative HER2-specific IFN-γ:IL-10 production was significantly higher in pCR (62.0:38.0 %) compared with non-pCR (23.8:76.2 %) patients. Absolute IFN-γ:IL-10 production ratio changed from 1.6:1 (pCR) to 0.3:1 (non-pCR) (bottom left panel). No relative shifts in IFN-γ:IL-4 production were observed to positive controls (anti-CD3/CD28 or anti-CD3, respectively) (bottom right panel); *p <0.05, ** p <0.01, *** p <0.001

To determine the functional contribution of Th2 and Treg phenotypes, HER2-specific IL-4 and IL-10 production were examined via ELISPOT, respectively. While overall anti-HER2 IL-4pos responsivity, repertoire, and cumulative response did not differ between pCR and non-pCR cohorts, donor-matched HER2-specific IFN-γ:IL-4 production ratios shifted from 2.8:1 (relative Th1-favoring phenotype) in pCR to 0.5:1 (relative Th2-favoring) in non-pCR patients (p <0.001; Fig. 4b). Similarly, overall anti-HER2 IL-10pos immune metrics did not differ between pCR and non-pCR patients; however, relative anti-HER2 IFN-γ:IL-10 contributions shifted from 1.6:1 (Th1-favoring) in pCR to 0.3:1 (Treg-favoring) in non-pCR patients (p = 0.008; Fig. 4c).

Th1 deficit in patients with non-pCR is unrelated to immune incompetence, host-level T cell anergy or immunosuppressive phenotypes

Immune competence in pCR and non-pCR subgroups was assessed by anti-CD3/anti-CD28-stimulated Th1 responses using IFN-γ ELISPOT. Mean anti-CD3/CD28 responses did not differ (1195 ± 87.4 vs 1085 ± 70.7 SFC/2 × 105 cells, p = 0.23) between pCR and non-pCR cohorts. Furthermore, IFN-γ production following recall stimuli (tetanus toxoid (105 ± 20.9 vs 98 ± 11.6 SFC/2 × 105), and Candida albicans (182 ± 29.8 vs 181 ± 9.0 SFC/2 × 105)) were similar between pCR and non-pCR groups, respectively (Fig. 5a). Collectively, these data suggest that the anti-HER2 Th1 disparity is not attributable to host-level T cell anergy or impaired antigen-presenting capacity in patients with non-pCR PBMC.
Fig. 5

Anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) deficit in patients without pathologic complete response (non-pCR) is not attributable to lack of immune competence, host-level T cell anergy, or increase in immunosuppressive phenotypes. Peripheral blood mononuclear cells (PBMC) from pCR and non-pCR patients did not differ significantly in (a) immune competence – measured by IFN-γ production to anti-CD3/anti-CD28 stimulus or recall stimuli tetanus toxoid and Candida albicans – by enzyme-linked immunosorbent spot. Results presented as median ± IQR interferon-γ (IFN-γ) spot-forming cells (SFC)/2 × 105 cells. b, c Relative proportions of CD3+CD4+ (b, top) or CD3+CD8+ T-cells (b, bottom), Treg (CD4+CD25+FoxP3+) (c, top) or myeloid-derived suppressor cells (MDSC) (CD11b+CD33+HLA-DRCD83) (c, bottom) by flow cytometry. Representative stains within groups are shown; results in histograms are expressed as mean proportions (%) ± standard error of the mean as indicated

On flow cytometry, the mean proportion of CD3+CD4+ (69.6 ± 6.2 % vs 68.5 ± 3.1 %, p = 0.87) and CD3+CD8+ (23.5 ± 4.5 % vs 25.9 ± 2.9 %, p = 0.67) cells did not differ between PBMCs from pCR and non-pCR patients, respectively (Fig. 5b). Proportions of B cells (CD19+) and natural killer (NK) cells (CD3CD16+) were similar between groups (data not shown). Circulating immunosuppressive phenotypes were compared: mean proportions of CD4+CD25+FoxP3+ cells (Treg) (0.95 ± 0.5 % vs 0.88 ± 0.3 %, p = 0.89), and CD11b+CD33+HLA-DRCD83 cells (myeloid-derived suppressor cells (MDSC)) (0.6 ± 0.1 % vs 0.9 ± 0.3 %, p = 0.34) did not differ between pCR and non-pCR subgroups, respectively (Fig. 5c).

Anti-HER2 Th1 deficit in patients with non-pCR can be corrected with HER2-targeted CD4+ Th1 immune interventions

We have previously demonstrated that intranodally injected HER2-pulsed DC1s elaborate abundant IL-12p70 and polarize naïve CD4+ T-cells to IFN-γ/TNF-α-producing anti-HER2 Th1 in vivo [12, 18]. When employed in HER2pos ductal carcinoma in situ (DCIS) and patients with stage I HER2pos IBC in phase I/II trials, autologous HER2-targeted DC1 vaccination resulted in durable anti-HER2 Th1 immunity; pCR rates approached 25 % with substantial loss of target antigen in the remainder of patients (unpublished data) [15, 19].

In order to determine the impact of HER2-Th1-targeted immune interventions in high-risk non-pCR patients, four non-pCR patients (cohort G; Fig. 1) were recruited to our phase I adjuvant HER2-pulsed DC1 vaccination trial (NCT02061423); demographic and clinicopathologic characteristics of enrolled patients are detailed in Table 3. Subjects received six weekly injections followed by three booster doses at three-month intervals. Vaccination-induced anti-HER2 Th1 responses were followed prospectively; Th1 reactivity in individual patients pre-vaccination and post-vaccination is illustrated in Fig. 6a. In vaccinated subjects, evaluable anti-HER2 Th1 responses measured 6 months post-vaccination (i.e., prior to the third booster) indicated significantly improved anti-HER2 Th1 repertoire (3.7 ± 0.5 post-vaccination vs 0.5 ± 0.5 pre-vaccination, p = 0.014) and cumulative response (192.3 ± 16.4 vs. 33.9 ± 19.4 SFC/106, p = 0.014) compared with pre-vaccination levels (Fig. 6b). Vaccinations were well-tolerated, with only two cases of grade-1 toxicity observed.
Table 3

Demographic and clinicopathologic characteristics of patients recruited to the ongoing phase I trial of HER2-pulsed DC1 vaccination in HER2pos IBC patients with residual disease following neoadjuvant trastuzumab and chemotherapy (NCT02061423)

Subject

Age, y

HLA

Race

Menopausal status

ER

PR

HER2

T + C regimen

Surgery

yp stage

26113-01

67

A2

White

Postmenopausal

+, 30 %

+, 5 %

3+, >90 %

AC/TH

MRM

T1b N2a

26113-02

35

A2

White

Premenopausal

+, 30 %

+, 4 %

2+, FISH +

AC/TH

MRM

T2 N2a

26113-03

45

-

White

Premenopausal

+, 84 %

-, 3 %

3+, >10 %

AC/TH

MRM

Tis N0

26113-04

55

-

White

Postmenopausal

−, 0 %

-, 0 %

3+, >10 %

TC

MRM

T1c N1mi

HER2 human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic cell, IBC invasive breast cancer, HLA human leukocyte antigen (A2 yes/no), ER estrogen receptor, PR progesterone receptor, T + C trastuzumab and chemotherapy, yp post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, MRM modified radical mastectomy, FISH fluorescence in situ hybridization, TC Taxotere, Cyclophosphamide

Fig. 6

Depressed anti-human epidermal growth factor receptor 2 (anti-HER2) T-helper type-1 (Th1) immunity is restored following HER2-pulsed type 1-polarized dendritic cell (DC1) immunization. a Anti-HER2 CD4+ T cell immune reactivity profiles in four patients with non-pCR (UPCC # 26113–01 to −04) undergoing HER2-pulsed DC1 vaccination in the ongoing phase I trial NCT02061423 are demonstrated at three time points: pre-vaccination (black), 3 months post vaccination (gray), and 6 months post vaccination (white). For these time points, responses to individual HER2-derived class II peptides (x-axis; p42, p98, p328, p776, p927, p1166) are graphed, with anti-CD3/CD28 serving as positive control. Anti-HER2 Th1 repertoire and cumulative responses at these time points are listed in adjoining tables. b Anti-HER2 Th1 repertoire (mean # of reactive peptides) and cumulative response (mean total SFC/10 6 cells) increase progressively in patients with non-pCR at the 3-month and 6-month time points. SFC spot-forming cells

Discussion

In the present study, we identify a novel systemic immune correlate to pathologic response following neoadjuvant HER2-targeted therapy in patients with HER2pos IBC. Although not globally improved in all patients treated with T + C, anti-HER2 CD4+ T-cell immunity is more robust in patients achieving pCR compared with their non-pCR counterparts despite controlling for relevant demographic and tumor-related confounders. HER2-specific Th1, but not Th2, CD4+ T-cells appear to be the dominant contributor to the circulating anti-HER2 IFN-γ+ immune disparity; this anti-HER2 Th1 deficit is not attributable to host-level T cell anergy, lack of immunocompetence, or preponderance of immunosuppressive phenotypes in non-pCR patients. Importantly, this anti-HER2 Th1 deficit is modifiable, and can be corrected with HER2-pulsed DC1 vaccinations. In high-risk non-pCR patients, strategies to boost anti-HER2 Th1 immunity may be of benefit.

Pathologic complete response following neoadjuvant administration of HER2-targeted therapies is a reliable surrogate for favorable long-term outcomes in HER2pos BC [7, 8]; in fact, the Food and Drug Administration (FDA) supports pCR as a trial endpoint for drug approval [20]. Conversely, non-pCR portends a worse overall prognosis. Recent investigation has elucidated tumor cell-level mechanisms that account for suboptimal responses to HER2-targeted therapies, including overexpression of EGFR, cMYC, or ERBB3, and mutational loss of PTEN or activation of PI3K [21]. Beyond these factors, and the known association between ER negativity [8] – which is not readily modifiable – and pCR, there is a relative void in our understanding of host-level factors that impact response to HER2-directed therapies. In the current study, heightened circulating anti-HER2 CD4+ Th1 immune responses correlate strongly with pCR; conversely, the association of an anti-HER2 Th1 immune deficit with non-pCR warranted a search for therapeutic strategies that might correct this deficit. Fortunately, even in these heavily pre-treated patients, the Th1 deficit did not appear to be immunologically fixed and could be rectified with appropriate HER2-directed Th1 interventions. Thus, while a strategy such as withholding HER2-targeted therapies in patients with negatively prognostic tumor-level genetic alterations (e.g., PI3K mutations) is impractical [22], augmenting the depressed anti-HER2 Th1 immunity in non-pCR patients may be more feasible as an adjunct to existing HER2-targeted therapies to improve clinical outcomes.

CD4+ Th1 cells have emerged as critical components of antitumor immunity. Via expression of T-bet and IFN-γ, Th1 cells indirectly mediate antitumor effects by enhancing CD8+ cytotoxic T-lymphocyte and NK cell function [23]. In addition, via elaboration of IFN-γ and TNF-α, HER2-specific Th1 cells – in synergism with trastuzumab-mediated HER2 blockade – directly promote senescence and apoptosis, as well as HER2-specific CD8+ T cell targeting of HER2-overexpressing tumors in vitro [10, 24]. Indeed, the association between improved HER2369–377-specific CD8 + T-cell immune responses and tumor eradication in pCR patients may reflect the ready availability of CD4+ T cell help. Moreover, a recent genomic analysis from the NCCTG-N9831 trial demonstrated a strong association between increased relapse-free survival in adjuvant trastuzumab-treated patients and a signature of immune function genes, including IFN-γ and TNF-α [21]. In the present study, a relative decay in circulating anti-HER2 T-bet+IFN-γ+ (i.e., Th1), but not GATA-3+IFN-γ+ (i.e., Th2), phenotypes is associated with persistence of HER2pos tumors following neoadjuvant T + C. Taken together, these data suggest that abrogation of immunologic, particularly anti-HER2 Th1 function, may represent a HER2pos tumor-driven mechanism to evade immune surveillance during T + C treatment. Immune interventions aimed at restoring anti-HER2 Th1 function may be valuable in improving pathologic response following neoadjuvant T + C.

In parallel with these observations, growing evidence indicates that robust cellular immune responses in the tumor microenvironment are associated with improved outcomes in BC [25], particularly in HER2pos subtypes [26]. Furthermore, an analysis from the GeparQuattro trial suggested that tumor-infiltrating lymphocyte (TIL) density correlates with pCR following neoadjuvant T + C; for every 10 % increase in TIL levels, a 16 % increase in pCR rates was observed [27]. The sizeable increase in circulating anti-HER2 Th1 populations in pCR patients in the present study may represent a systemic corollary to such immune-related changes in the tumor microenvironment, and lend further support to evidence that intact immune functionality, in addition to HER2-signaling inhibition, is critical in mediating antitumor effects following T + C treatment [28]. What is not immediately evident from our analysis, however, is whether the heightened anti-HER2 Th1 responses in pCR patients represent preservation of erstwhile immunity, or immune restoration following T + C treatment. If the latter is true, these data may further support immune restorative neoadjuvant interventions in order to improve pathologic response.

Other limitations merit discussion. First, given the retrospective and exploratory nature of the study design, the findings herein should be interpreted as hypothesis-generating and warrant large-scale validation. Second, despite minimal demographic/clinical variability between treatment-naïve T + C - treated HER2pos - IBC cohorts, the global lack of improvement in anti-HER2 Th1 responses following T + C treatment must be interpreted with caution, since these data were derived from an unpaired comparison between independent patient samples. Finally, while encouraging, definitive conclusions regarding the immune restorative impact of HER2-directed DC1 vaccination in high-risk non-pCR patients, cannot be drawn until completion and final reporting of this ongoing trial.

The translational implications of these findings bear emphasis. As discussed, they may justify addition of HER2-targeted Th1 immune interventions to neoadjuvant T + C regimens and/or in the adjuvant setting for high-risk non-pCR subgroups. Moreover, in light of our recent demonstration that depressed anti-HER2 Th1 immunity correlates with subsequent recurrence in patients treated with adjuvant T + C [10], monitoring high-risk patients with non-pCR for real-time fluctuations in anti-HER2 Th1 immunity may complement existing radiographic surveillance, and identify critical opportunities for therapeutic intervention. Incorporation of anti-HER2 Th1 immune detection protocols in future clinical trial design, particularly those investigating neoadjuvant HER2-targeted therapies, appears justified.

Conclusions

In summary, this is the first description, to our knowledge, of a critical association between anti-HER2 CD4+ Th1 immunity and pCR following neoadjuvant T + C in HER2pos IBC patients. Although our data cannot confirm causality, the dramatic IFN-γ+ anti-HER2 Th1 deficit observed in non-pCR patients following neoadjuvant T + C raises the possibility that immune rescue with HER2-Th1 interventions may complement standard HER2-targeted strategies in improving outcomes in these high-risk patients. While correction of the anti-HER2 Th1 immune deficit has already been observed in non-pCR patients recruited to our HER2-DC1 vaccination trial, longitudinal follow up and larger-scale studies will establish if such immune manipulations ultimately mitigate recurrence in such patients.

Abbreviations

BC: 

breast cancer

BMI: 

body mass index

DC: 

dendritic cell

DC1: 

type 1-polarized dendritic cell

DMEM: 

Dulbecco’s modified Eagle’s medium

ELISPOT: 

enzyme-linked immunosorbent spot

ER: 

estrogen receptor

FACS: 

fluorescence-activated cell sorting

FCS: 

fetal calf serum

FISH: 

fluorescence in situ hybridization

GM-CSF: 

granulocyte monocyte colony stimulating factor

HER2: 

human epidermal growth factor receptor 2

HER2pos

human epidermal growth factor receptor 2-positive

IBC: 

invasive breast cancer

iDC: 

immature dendritic cells

IFN: 

interferon

IHC: 

immunohistochemistry

IL: 

interleukin

LPS: 

lipopolysaccharide

MDSC: 

myeloid-derived suppressor cells

MHC: 

major histocompatability complex

NK: 

natural killer

NIH: 

National Institutes of Health

OR: 

odds ratio

PBMC: 

peripheral blood mononuclear cells

PBS: 

phosphate-buffered saline

pCR: 

pathologic complete response

PMA: 

phorbol-12-myristate 13-acetate

PR: 

progesterone receptor

PVDF: 

polyvinylidene fluoride

RT: 

room temperature

SFC: 

spot-forming cells

T + C: 

trastuzumab and chemotherapy

Th1: 

T-helper type-1

TNF-α: 

tumor necrosis factor- α

Declarations

Acknowledgements

The study was supported by National Institutes of Health R01 CA096997, Pennies in Action® (www.penniesinaction.org), and University of Pennsylvania Abramson Cancer Center Breast Translational Center of Excellence Grant. The authors thank Jeanne Kobilnyk and Vickie Sallee for assistance in conducting the vaccine trial, the staff of the General Clinical Research Center, and the Leukapheresis Unit at the Hospital of the University of Pennsylvania.

Authors’ Affiliations

(1)
Department of Surgery, University of Pennsylvania Perelman School of Medicine, Rena Rowen Breast Center
(2)
Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine
(3)
Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine
(4)
Department of Pathology, University of Pennsylvania Perelman School of Medicine
(5)
Rena Rowen Breast Center, Hospital of the University of Pennsylvania

References

  1. Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. J Am Coll Surg. 2002;194(4):488–501.View ArticlePubMedGoogle Scholar
  2. Wang GS, Zhu H, Bi SJ. Pathological features and prognosis of different molecular subtypes of breast cancer. Mol Med Rep. 2012;6(4):779–82.PubMedGoogle Scholar
  3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.View ArticlePubMedGoogle Scholar
  4. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–46.View ArticlePubMedGoogle Scholar
  5. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84.View ArticlePubMedGoogle Scholar
  6. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024–31.View ArticlePubMedGoogle Scholar
  7. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351–7.View ArticlePubMedGoogle Scholar
  8. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013;24(8):1999–2004.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sanchez-Rovira P, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014;110(5):1139–47.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, et al. Progressive loss of anti-HER2 CD4+ T-helper Type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 2015;4(8):e1022301. DOI:10.1080/2162402X.2015.1022301.
  11. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5(6):1289–97.PubMedGoogle Scholar
  12. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012;35(1):54–65.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Guerkov RE, Targoni OS, Kreher CR, Boehm BO, Herrera MT, Tary-Lehmann M, et al. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J Immunol Methods. 2003;279(1–2):111–21.View ArticlePubMedGoogle Scholar
  14. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, et al. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 2008;9:9.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012;118(17):4354–62.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 2002;295(5553):338–42.View ArticlePubMedGoogle Scholar
  17. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997;89(4):587–96.View ArticlePubMedGoogle Scholar
  18. Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003;21(20):3826–35.View ArticlePubMedGoogle Scholar
  19. Datta J, Terhune JH, Lowenfeld L, Cintolo JA, Xu S, Roses RE, et al. Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med. 2014;87(4):491–518.PubMedPubMed CentralGoogle Scholar
  20. Federal Drug Agency. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf. Accessed 12 March 2015.
  21. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015;33(7):701–8.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Henry NL, Schott AF, Hayes DF. Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utility. J Clin Oncol. 2014;32(29):3207–9.View ArticlePubMedGoogle Scholar
  23. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91–8.View ArticlePubMedGoogle Scholar
  24. Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell D, et al. CD4+ T-helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER-2/neu-expressing Cancers. Cancer Immunol Res. 2015;3(5):455–63.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.View ArticlePubMedGoogle Scholar
  26. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669–76.View ArticlePubMedGoogle Scholar
  27. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer. Cancer Res. 2013;73:S1–05.Google Scholar
  28. Bellati F, Napoletano C, Ruscito I, Liberati M, Panici PB, Nuti M. Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy. J Clin Oncol. 2010;28(21):e369–70.View ArticlePubMedGoogle Scholar

Copyright

© Datta et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement